Reports Q1 revenue $6.47M, consensus $13.55M. The decrease in revenue was primarily due to decreased revenue recognized under Neurocrine collaboration agreements. “Voyager ended the first quarter of 2025 with a strong cash position of $295 million, which we expect to provide runway into mid-2027. This runway guidance does not include potential milestone payments from existing partnerships, such as the up to $35 million we could earn in 2025-2026 from the Neurocrine-partnered FA and GBA1 programs,” said Alfred Sandrock, Chief Executive Officer of Voyager. “We continue to thoughtfully and strategically advance our pipeline, including our two wholly-owned tau targeting programs VY7523 and VY1706 for Alzheimer’s disease, as well as the FA and GBA1 programs, which are advancing towards INDs this year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Promising Developments in Alzheimer’s Treatments Support Buy Rating for Voyager Therapeutics
- Promising Developments in Voyager Therapeutics’ Alzheimer’s Programs Highlight Potential of Dual Tau-Targeted Therapies
- Voyager updates on Alzheimer’s programs ‘compelling,’ says H.C. Wainwright
- Voyager Therapeutics announces new data from two preclinical programs
- Voyager Therapeutics: Strategic Positioning and Growth Prospects Reinforce Buy Rating